Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

Trial Profile

Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Degarelix (Primary) ; Bicalutamide; Gonadotropin releasing hormone stimulants
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms Degarelix Pre-Op
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2016 Results assessing treatment effect on intratumoral dihydrotestosterone levels published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 10 May 2016 Results (n=39) presented at the 111th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top